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Background. Two clinical phenotypes of diabetic kidney disease (DKD) have been reported, that is, with or without increased
albuminuria. The aim of study was to assess the usefulness of urinary neutrophil gelatinase-associated lipocalin (uNGAL) for the
early diagnosis of DKD in the type 2 diabetes mellitus (T2DM). Methods. The study group consisted of 123 patients with T2DM
(mean age 62± 14 years), with urine albumin/creatinine ratio (uACR)< 300mg/g and eGFR≥ 60ml/min/1.73m2.The control group
included 22 nondiabetic patients with comparable age, sex, and comorbidities. uNGAL, albumin, and creatinine were measured
in the first morning urine samples. uACR and uNGAL/creatinine ratios (uNCR) were calculated. Results. In the control group,
maximum uNCR was 39.64 𝜇g/g. In T2DM group, 24 patients (20%) had higher results, with the maximum value of 378.6𝜇g/g.
Among patients with uNCR > 39.64 𝜇g/g, 13 (54%) did not have markedly increased albuminuria. Women with T2DM had higher
uNCR thanmen (𝑝 < 0.001), without difference in uACR (𝑝 = 0.09). uNCR in T2DM patients correlated significantly with HbA1c.
Sex, total cholesterol, and uACRwere independent predictors of uNCR above 39.64 𝜇g/g.Conclusions. Increased uNGAL and uNCR
may indicate early tubular damage, associated with dyslipidemia and worse diabetes control, especially in females with T2DM.
1. Introduction
Diabetes is a group of metabolic diseases characterized
by heterogenic pathophysiology and clinical manifestations.
Type 2 diabetes (T2DM) is the most frequent type of car-
bohydrate metabolic disorders; it is estimated that T2DM
comprises 90–95% of all cases. In most countries, T2DM
prevalence is constantly increasing, and the increase is faster
than the population growth [1]. In addition, a major medical
problem is the increasing morbidity and mortality from
complications of diabetes, affecting eyes, kidneys, heart,
cardiovascular, andnervous system [2]. Inmost countries, the
diabetic kidney disease (DKD) is the most common cause of
nephropathies requiring renal replacement therapy [3]. Mor-
phological changes in kidneys in diabetes are induced by dis-
orders of kidney metabolism caused by increased glycemia,
as well as by changes in renal hemodynamics, or activation
of the renin-angiotensin-aldosterone system (RAA). In a
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substantial proportion of T2DM patients, structural changes
in kidneys as well as the structural-functional relationships
differ from the classical Kimmelstiel-Wilson nodular sclero-
sis observed in type 1 diabetes (T1DM) [4]. In particular,
histopathological studies suggest tubular involvement in
about 40% of patients with DKD associated with T2DM,
and tubular changes in these patients are unproportionate
comparing with glomerular pathology [4–6]. Literature pro-
vides convincing evidence that changes in kidneys of T2DM
patients are more heterogenic than in T1DM [4–7].
Neutrophil gelatinase-associated lipocalin (NGAL) was
first identified in activated neutrophils. It belongs to the
lipocalin protein family, and it is able to bind and transport
small ligands [8]. Under physiological conditions NGAL is
expressed at very low levels in kidneys, trachea, lungs, stom-
ach, and colon. It is present in blood in low concentrations
and it undergoes free glomerular filtration followed by nearly
complete resorption in the mechanism of megalin-mediated
endocytosis in the renal proximal tubule. Increased NGAL
synthesis in response to a damaging factor in the distal
convoluted tubule and urinary secretion of NGAL constitute
the major fraction of urinary NGAL [9, 10]. NGAL as an
early biomarker of kidney damage was identified in 2003
during studies searching for novel markers of ischemic and
toxic kidney injury in patients undergoing cardiac surgery
[9]. The urinary concentrations of NGAL (uNGAL) increase
in a consequence of tubular dysfunction associatedwith acute
kidney injury caused by ischemia and secondary tubular
damage [9]. Studies suggest that uNGALmay be an appropri-
ate biomarker of tubular changes in chronic kidney disease
including DKD, both in T2DM and in type T1DM [11–13].
The studies of Fu et al. [14] and Kim et al. [15] suggested
important role of uNGAL measurements in early diagnosis
of DKD. Among patients with T2DM, an increase in uNGAL
significantly correlated with a decrease in GFR [11, 16].
The aim of the study was to assess the function of renal
tubules in patients with early-stage T2DM as reflected by
uNGAL concentrations in a group of T2DM patients at the
early stage of DKD, that is, with eGFR ≥ 60ml/min/1.73m2
and urine albumin/creatinine ratio (uACR) < 300mg/g.
2. Materials and Methods
The study was conducted in accordance with the Declaration
of Helsinki and received permission from the Bioethics
Committee of the Regional Medical Chamber in Rzeszo´w,
Poland (number 70/2014/B).
The study recruited adult patients with T2DM who were
referred to the ambulatory specialist nephrological care by
their diabetologist. Between 2014 and 2015, 123 patients
were enrolled in the study. Inclusion criteria were eGFR
(2009 Chronic Kidney Disease, Epidemiology Collabora-
tion, CKD-EPI equation) >60ml/min/1.73m2 and no overt
proteinuria (uACR < 300mg/g). Only patients who signed
the informed consent were included in the study. Exclusion
criteria were treatment with nephrotoxic medications, other
kidney diseases, urinary tract infections, systemic infections,
cancer, allergy, systemic connective tissue diseases, anemia,
pregnancy, and nonstable hypertension (≥130/90mmHg in
self-monitoring). Additionally, a control group included 22
nondiabetic patients with age, sex, and comorbidities sim-
ilar to T2DM patients; this allowed comparison of labo-
ratory results. The control group included adult patients
of the nephrological ambulatory with eGFR CKD-EPI >
60ml/min/1.73m2 and no overt proteinuria. These were
mainly patients with stable arterial hypertension, or benign
simple kidney cysts. Two control patients suffered in the past
infections of the lower urinary tract; one patient was diag-
nosed with duplication of renal pelvis. The exclusion criteria
were the same as for T2DM patients.
First morning urine samples were taken from patients
and controls for the measurements of uNGAL, albumin,
and creatinine concentrations, as well as for the general
urine examination.The concentrations of uNGAL were mea-
sured with the automated chemiluminescent microparticle
immunoassay on the ARCHITECT analyzer (Abbott Diag-
nostics, Abbott Park USA). Urine albumin was measured
with immunoturbidimetry and urine creatinine with enzy-
matic method using Olympus AU680 biochemistry analyzer
(Olympus, Center Valley, PA, USA). The results of the
measurements were used to calculate uACR and uNGAL/
creatinine ratio (uNCR). Other laboratory results were
obtained as a part of routine patients’ assessment performed
in nephrology ambulatory.
2.1. Statistical Analysis. A number of patients (percentage
of the group) are reported for qualitative variables. Mean
± standard deviation or median (lower-upper quartile) are
shown for normally or nonnormally distributed quantitative
variables, respectively. The distributions of the variables
were assessed with Shapiro-Wilk’s test. The 𝑡-test or Mann-
Whitney’s U test was used to study differences between
the groups. The variables that differed significantly between
patients with high and low uNCRwere used as predictor vari-
ables in multiple regression analysis. Odds ratios with 95%
confidence intervals were reported for multiple regression
analysis. Spearman’s correlation coefficients are reported for
correlations. All the tests were two-tailed and the results at
𝑝 < 0.05 were considered statistically significant.
3. Results
The group of T2DM patients did not differ from the control
group participants in terms of age, sex, eGFR, or cardiovas-
cular comorbidities, but they had higher BMI (Table 1). Also,
the average concentrations of urine albumin and NGAL, as
well as the values of uACR and uNCR, did not differ between
diabetic patients and control subjects (Table 1). However, the
maximum uNCR in the control group was 39.64 𝜇g/g and,
among studied T2DM patients, 24 (20%) had higher values,
with the maximum of 378.6 𝜇g/g.
T2DM patients with uNCR above the maximum con-
trol value were characterized by higher triglycerides, total
cholesterol, and LDL-cholesterol, as well as higher urine
albumin and uACR as compared to patients with lower
uNCR (Table 2). The correlation between uNCR and uACR
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Table 1: Characteristics of studied patients.
Control patients (𝑁 = 22) T2DM patients (𝑁 = 123) 𝑝 value
Age, years 57 ± 15 62 ± 13 0.1
Male gender,𝑁 (%) 9 (41) 57 (46) 0.7
BMI, kg/m2 28 ± 6 32 ± 6 0.009
eGFR, ml/min/1.73m2 87 ± 15 90 ± 17 0.3
Hypertension,𝑁 (%) 15 (68) 98 (80) 0.2
Ischemic heart disease,𝑁 (%) 3 (14) 24 (19) 0.5
Heart failure,𝑁 (%) 3 (14) 9 (7) 0.3
Dyslipidemia,𝑁 (%) 19 (95) 111 (95) 1.0
Treatment with ACEI or ARB,𝑁 (%) 12 (55) 86 (70) 0.2
Urine albumin, mg/l 5.9 (3.0–22.9) 8.0 (3.2–18.0) 0.6
uACR, mg/g 6.0 (3.6–9.0) 7.3 (3.4–19.2) 0.3
Urine NGAL, 𝜇g/l 10.9 (6.0–38.2) 15.3 (6.4–29.6) 0.7
uNCR, 𝜇g/g 12.2 (5.9–27.9) 13.5 (6.5–31.4) 0.3
T2DM, type 2 diabetes mellitus; BMI, body mass index; eGFR, estimated glomerular filtration rate; ACEI, angiotensin-converting enzyme inhibitors; ARB,
angiotensin receptor blockers; uACR, urine albumin/creatinine ratio; NGAL, neutrophil gelatinase-associated lipocalin; uNCR, urine NGAL/creatinine ratio.
Table 2:The differences between T2DM patients with urine NGAL to creatinine ratio (uNCR) below and above the maximum control value.
T2DM patients with uNCR ≤
39.64 𝜇g/g (𝑁 = 99)
T2DM patients with uNCR >
39.64 𝜇g/g (𝑁 = 24) 𝑝 value
Age, years 62 ± 12 62 ± 17 0.9
Men,𝑁 (%) 54 (55) 3 (12) <0.001
BMI, kg/m2 32 ± 5 32 ± 7 0.9
Treatment with ACEI or ARB,𝑁 (%) 67 (68) 19 (79) 0.3
T2DM duration, years 6 (1–10) 6 (5–12) 0.5
Newly diagnosed diabetes,𝑁 (%) 27 (27) 4 (16) 0.3
Ophthalmologic examination,𝑁 (%) 83 (84) 11 (46) <0.001
Retinopathy,𝑁 (% of examined) 17 (20) 2 (18) 0.9
HbA1c, %/mmol/mol 6.50 (5.90–8.50)/47.5 (41.0–69.4) 6.95 (6.10–8.60)/52.5 (43.2–70.5) 0.4
eGFR, ml/min/1.73m2 90 ± 17 91 ± 20 0.9
Triglycerides, mmol/l 1.56 (1.20–2.03) 2.42 (1.40–3.39) 0.021
Total cholesterol, mmol/l 4.59 (3.83–5.72) 5.74 (4.55–7.14) 0.003
LDL-cholesterol, mmol/l 2.60 (1.95–3.61) 3.69 (2.40–4.47) 0.004
HDL-cholesterol, mmol/l 1.19 (0.96–1.46) 1.23 (1.06–1.40) 0.5
Urine albumin, mg/l 6.8 (3.0–12.9) 16.3 (10.7–35.9) 0.003
uACR, mg/g 4.8 (3.1–13.0) 16.0 (9.1–50.0) <0.001
uACR < 30mg/g,𝑁 (%) 84 (88) 13 (54) <0.001
T2DM, type 2 diabetes mellitus; BMI, body mass index; eGFR, estimated glomerular filtration rate; ACEI, angiotensin-converting enzyme inhibitors; ARB,
angiotensin receptor blockers; uACR, urine albumin/creatinine ratio; NGAL, neutrophil gelatinase-associated lipocalin; uNCR, urine NGAL/creatinine ratio.
was highly significant (Figure 1(a)). Still, in 13 (54%) of
the 24 patients with high uNCR values, uACR was below
30mg/g and ranged from 2.35 to 16.10mg/g. Interestingly, the
patients with high uNCR were mainly women (𝑁 = 21, i.e.,
88%). Women with T2DM had significantly higher uNCR
than men [24.23 (8.89–56.80) versus 11.40 (3.36–18.02) 𝜇g/g;
𝑝 < 0.001], without significant difference in uACR [8.87
(3.41–33.45) versus 5.33 (3.15–13.28)mg/g; 𝑝 = 0.09]. The
average concentrations of uNGAL were also higher in DMT2
women thanmen, although the differencewas not statistically
significant [17.15 (7.60–43.90) versus 13.70 (6.10–23.80) 𝜇g/l;
𝑝 = 0.1].
Among 123 T2DMpatients, 94 (76%) underwent the oph-
thalmologic examination, including 83 with low uNCR and 11
with high uNCR. We did not observe significant associations
between uNCR and the presence of diabetic retinopathy
(Table 2). Age, eGFR, and BMI values, as well as known dia-
betes duration, did not differ between the groups with uNCR
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Figure 1:The associations between uNCR and uACR (a) andHbA1c (b) amongT2DMpatients.The reference lines denote uNCR= 39.64 𝜇g/g
(i.e., maximum in the control group), uACR = 30mg/g, and HbA1c = 7%.
Table 3: Multiple linear regression to predict uNCR > 39.64 𝜇g/g in patients with T2DM.
Dependent variables Odds ratio (95% confidence interval) 𝑝 value
Women 7.98 (1.90–33.3) 0.004
Triglycerides, per 1mmol/l 1.26 (0.73–2.16) 0.4
Total cholesterol, per 1mmol/l 1.83 (1.15–2.91) 0.009
uACR, per 1mg/g 1.03 (1.004–1.05) 0.022
T2DM, type 2 diabetes mellitus; uACR, urine albumin/creatinine ratio; uNCR, urine NGAL/creatinine ratio.
above and below 39.64 𝜇g/g (Table 2). Although HbA1c was
significantly correlated with uNCR (Figure 1(b)), it did not
differ significantly between the patients with uNCR above
and below the maximum control value (Table 2). uNCR did
not correlate with eGFR (𝑅 = −0.14; 𝑝 = 0.1), age (𝑅 = 0.14;
𝑝 = 0.1), or time from T2DM diagnosis (𝑅 = 0.13; 𝑝 = 0.1).
uNCR was nonsignificantly higher among patients treated
with angiotensin-converting enzyme inhibitors (ACEI) or
angiotensin receptor blockers (ARB) comparing with those
not consuming the medications [15.87 (7.90–36.02) versus
9.72 (3.82–23.70) 𝜇g/g; 𝑝 = 0.053], while uACR did not
differ between the groups [7.89 (3.37–18.40) versus 4.58
(3.05–16.90); 𝑝 = 0.4]. In multiple logistic regression
(Table 3), sex, total cholesterol, and uACR were identified
as the independent predictors of high uNCR (i.e., above the
maximum control value of 39.64 𝜇g/g).
In control group, no significant correlation was observed
between uNCR and uACR. Also, there were no significant
differences between control men and women in uNGAL and
uNCR values. In contrast to DMT2 patients, uNGAL concen-
trations were nonsignificantly higher in control men [20.10
(7.40–48.40) versus 10.50 (6.00–20.30) 𝜇g/l;𝑝= 0.1]; however,
uNCR was nonsignificantly higher in control women [12.53
(6.42–28.81) versus 7.73 (5.92–13.69) 𝜇g/g; 𝑝 = 0.3].
4. Discussion
In most cases, recognition of the diabetic kidney disease
(DKD) is based on results of tests such as albuminuria,
creatininemia with the estimation of eGFR, or renal imaging.
Clinical symptoms of DKD appear late and are not character-
istic. In T1DM, DKD coexists with diabetic retinopathy that
can be detected in ophthalmologic examination. However, in
T2DM, DKDmay be present in patients without retinopathy
[17, 18]. Diabetic retinopathy is less frequent in T2DM
and is a poor predictor of type of nephropathy [18]. Our
results are consistent with these observations, as we did
not observe significant associations between uNCR and the
presence of retinopathy.However, our observations regarding
retinopathy must be treated with caution, as only a part of
patients underwent ophthalmologic examination.
Renal biopsy is performed only in a relatively small
number of T2DM patients. This usually happens during
advanced stages of the disease when serum creatinine is
elevated and overt proteinuria occurs. In T2DM patients,
the morphological abnormalities in kidneys and the clinical
course of DKD are varied. In this group of patients, not
only classical glomerular changes but also changes in renal
tubules and in the renal interstitium play an important role in
kidney failure [5, 6, 19]. In nearly 40%ofT2DMpatients, renal
biopsy does not reveal typical glomerular pattern as observed
in T1DM. In a substantial proportion of such patients,
biopsy results show disproportionately severe damage to the
tubulointerstitial tissue as well as hyaline changes in small
renal arteries [5, 6]. For these reasons, eGFR and albuminuria
(proposed by Kidney Diseases Improving Global Outcomes
initiative [20] for the clinical assessment and prediction of
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CKD progression) may be insufficient in the early assessment
of kidney function among T2DM patients. If albuminuria
and uACR, together with eGFR, are considered markers
of glomerular damage, then in the group of T2DM in our
study the occurrence of CKD stages G1, G2, and A1 can
only be suspected; we can, however, recognize stages G1,
G2, and A2. In turn, when the uNCR above 39.64 𝜇g/g (i.e.,
the maximum uNCR in the control group) is considered
a marker of tubular and interstitial damage, a subgroup of
20% of patients with tubular damage can be distinguished.
This tubular damage cannot be discovered during routine
nephrological diagnostic tests. More than half of the patients
in our study had normal uACR values according to the
current diagnostic criteria [20], that is, uACR lower than
30mg/g. In such patients, a clinicist may not become alert
enough to be able to recognize early nephropathy connected
with T2DM. Our study shows that especially in women with
T2DM with abnormal lipid profile and inadequate diabetes
control the diabetic kidney disease may be underdiagnosed.
The United Kingdom prospective diabetes study (UKPDS)
[21] indicates that in women with T2DM the decrease
in glomerular filtration is frequently not accompanied by
albuminuria. Similarly, in a study of Parving et al. [22], more
than 50% of patients had no albuminuria.The study analyzed
data from more than 24000 T2DM patients, nearly 80%
of whom had glomerular filtration above 60ml/min/1.73m2
[22].
Higher uNCRvalues inwomenwith T2DMare partly due
to lower urine creatinine excretion in women than in men.
Wehave observed this both inT2DMpatients and in controls.
However, control women had lower uNGAL concentrations
than control men while, among T2DM patients, uNGAL
was higher in women than in men. Thrailkill et al. [23]
observedhigher uNGALconcentrations in females compared
to males in subjects with T1DM [23]. Higher uNCR values
in women with T2DM suggest that the early stages of DKD
may be similarly common in both sexes or even more
common in women, although end-stage renal disease is in
fact more common in diabetic men [24–26]. Female gender
is protective against the development of end-stage renal
disease in nondiabetic renal disease [24, 27] but this gender-
protective effect is probably diminished in diabetes mellitus
[28, 29].
In our study, uNCR correlated positively with uACR in
the T2DM patients. This is consistent with the results of
Nielsen et al. [30], who observed correlation between uNGAL
and albuminuria among 177 patients with T2DM and normal
eGFR during 3.5 years of follow-up. Increased uNGAL
predicted the increase in urinary albumin excretion ranging
from “microalbuminuria” to “macroalbuminuria” and higher
concentrations of uNGAL were associated with a more rapid
deterioration of renal function [30]. Our study indicates that
patients with uNCR above 39.64 𝜇g/g had on average higher
albuminuria and uACR. Several pathomechanisms may be
listed as underlying this observation. If we assume DKD
with primary glomerular involvement, the increased urinary
excretion of NGAL may result from disrupted mechanisms
of protein transport involvingmegalin and cubilin, caused by
long-term, excessive reabsorption of albumin in tubules [31,
32]. Also, other substances that leak to primary urine through
the damaged glomerular barrier may cause tubular cells’
damage, hence initiating inflammation and the process of
renal interstitial fibrosis. This, in turn, contributes to further
kidney damage resulting in albuminuria cooccurring with
tubular proteinuria and increased urinary excretion ofNGAL
[33]. However, as clearly indicated in practice guidelines on
DKD [34], nephropathy other than early glomerular damage
may be responsible for the increased urinary excretion of
NGAL in diabetic patients. Hence, in our study, the increase
in uNCR in the group of patients with normal albumin-
uria may also be linked with primary tubular damage. In
diabetic patients, tubular cells are negatively affected by
hyperglycemic environment. This leads to the development
of inflammation in the tubulointerstitial tissue, increased pro-
duction of extracellular matrix, and epithelial-mesenchymal
transition of renal tubular cells [35]. In result of active
inflammation, the tubulointerstitial tissue is infiltrated by
leucocytes, including monocytes that differentiate into tissue
macrophages and initiate the repair process and induce fibro-
sis.Thismay lead to an increase in the values of uNCR and/or
uACR in some T2DM patients [36–38]. In our study, 20%
of T2DM patients had elevated uNCR (above the maximum
value in the control group), and less than half of those patients
had elevated albuminuria. Fu et al. [14] observed that tubular
damage defined by the increase in uNCR appears even in
patients with diabetes of short duration, and the uNGAL
may become a more promising and earlier marker of kidney
damage in T2DM than uACR. Similarly, in the study by Kim
et al. [15] nonalbuminuric proteinuria correlated significantly
with uNGAL in patients with early-stage DKD (eGFR ≥
60ml/min/1.73m2).
The majority of our patients were treated with angi-
otensin-converting enzyme inhibitors or angiotensin recep-
tor blockers as part of nephroprotection in DKD [34].
We have not observed statistically significant differences
in uNCR or uACR between patients treated with renin-
angiotensin-aldosterone (RAA) system blockade and those
not treated, although there was a tendency towards higher
uNCR in patients who were on such treatment. These results
may suggest poor protective effect of RAA blockade against
tubular changes in T2DM.This observation is consistent with
the results of Nielsen et al. [30] who reported no effects
of angiotensin-converting enzyme inhibitors treatment on
uNGAL concentration in patients with T2DM with normal
glomerular filtration rate and “microalbuminuria.”
In the present study, patients with better diabetes control
and less atherogenic lipid profile had also lower uNCR values.
There is evidence that, in T2DM patients with CKD stages 1
to 4, better glycemic control contributes to improved kidney
function and brings benefits to the vascular system [22, 39].
Also, some studies suggest that lowering total cholesterol
slows down the progression of renal disease in T2DM[40, 41].
As uNCR value may be considered a noninvasive indicator
of renal tubules’ function, the results of the present study
lead us to hypothesis that better diabetes control together
with the treatment of dyslipidemia may have a positive
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influence on the tubule function and probably also renal
interstitial changes. However, to validate this hypothesis,
further prospective studies on a larger population of T2DM
patients are required.
5. Conclusion
Combinations of biomarkers representing different mecha-
nisms of DKD pathogenesis may be helpful in the determi-
nation of a pattern of changes in kidney function, especially
in the heterogenic group of T2DM patients. Our results
suggest that the determination of uNCR in addition to uACR
and eGFR enables early detection of kidney disease in a
part of patients with T2DM. Our results should be treated
with caution, because of the limited numbers of T2DM
patients and low number of controls recruited. However, our
results suggest that uNCR values higher than a cut-off value
(39.64 𝜇g/g in our sample) may be an indicator of early dam-
age to renal tubules, especially in T2DM women with dys-
lipidemia and worse diabetes control. The results, especially
the cut-off value, should be validated in larger study.
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